Shen et al. verified these observations and showed that persisters of BRAF-mutated melanoma treated with BRAF/MEK inhibitors proceed to a metabolic switch from glycolysis to OxPhos supported by peroxisomal FAO and peroxisomal FAO inhibitor triggers the reduction in the emergence of persister cells [144]. This evidence concerns the gene BRAF and melanoma.